AVITA Medical appoints Cary Vance to Board of Directors, effective April 1, 2023

AVITA Medical, Inc.

Cary Vance appointed as non-executive director, effective April 1, 2023, serving until 2023 Annual Meeting.
Compensation: $70,000 annual cash, initial $210,000 stock grant (30% options, 70% RSUs), and $105,000 annual equity, subject to shareholder approval.
Vance has over 25 years healthcare leadership, currently President/CEO of Titan Medical; prior roles include Hansen Medical, Covidien, and GE Healthcare.
Board determined Vance meets independence standards; no material relationships or arrangements with the company.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Cary Vance

Director

RCEL · AVITA Medical, Inc.

Effective: 2023-04-01
Filed: March 21, 2023, 7:59 PM ET

On March 16, 2023, AVITA Medical, Inc. (the “Company”) issued a press release announcing the appointment of Cary Vance to its Board of Directors (the “Board”), effective April 1, 2023

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Cary Vance was appointed as Director at AVITA Medical, Inc..

Action: appointed
Role: Director

Exact text from the filing

On March 16, 2023, AVITA Medical, Inc. (the “Company”) issued a press release announcing the appointment of Cary Vance to its Board of Directors (the “Board”), effective April 1, 2023

View on SEC.gov

AVITA Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-075191

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.